Andorra vs Developing regions: Proportion of the target population who received a 3rd dose of
Andorra
96.0%
in 2024
Developing regions
66.0%
in 2024
Andorra rank
15th
Developing regions rank
12th
Proportion of the target population who received a 3rd dose of over time
- Andorra
- Developing regions
How they compare
Andorra currently reports 96.0% against 66.0% in Developing regions, a difference of 30.0%.
That makes Andorra's figure about 1.5 times Developing regions's.
Across all 11 years both countries report, Andorra has been ahead every year.
Andorra ranks 15th and Developing regions ranks 12th of 136 countries.
Andorra has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Andorra | Developing regions | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 94.2% | 38.8% | 55.3% | Andorra |
| 2020s | 95.2% | 56.4% | 38.8% | Andorra |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received a 3rd dose of, Andorra or Developing regions?
- Andorra, at 96.0% against 66.0% in Developing regions as of 2024.
- What is the difference in proportion of the target population who received a 3rd dose of between Andorra and Developing regions?
- 30.0%, with Andorra ahead.
- How many years of comparable data are there for Andorra and Developing regions?
- 11 years are reported by both, from 2014 to 2024.
- How do Andorra and Developing regions rank globally for proportion of the target population who received a 3rd dose of?
- Andorra ranks 15th and Developing regions ranks 12th of 136 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received a 3rd dose of pneumococcal conjugate (PCV3) vaccine (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.